Investment briefing

Interim data release: November 2023:
Longevity Clinics Survey 2023
Read now
Edging ahead in Q3 but still held back:
Q3 2023: longevity investment report
Read now
Edging ahead in Q2 but still held back:
Q2 2023: longevity investment report
Read now
Investment review for January to March 2023. “If you’re going through hell, keep going.” Winston Churchill:
Q1 2023: longevity investment report
Read now
Full year 2022 report on the state of longevity investment: the numbers, the sectors, the top deals, the key players and the outlook for 2023:
Annual Longevity Investment Report
Read now
Disease management to disease modification – removing plaque to undo atherosclerosis:
Read now
Delaying the menopause to increase women’s healthspan:
Reproductive longevity
Read now
Leading a new era of personalised, preventative health and optimal aging:
Longevity diagnostics
Read now
Supplementing your Longevity supplement knowledge:
Longevity supplements
Read now
Managing senescent cells to drive human longevity:
Read now


Matter emerges from stealth with $26m to find a biomarker for happiness

Neuroscience company seeks to harness healthy neurotransmitter activity to help humans live

Denali raises $500m to advance treatments for neurodegenerative disease

Company targets neurodegeneration using large molecule biotherapeutics designed to cross the blood-brain

Yuva Bio raises $7.5m and partners on hair loss treatment targeting mitochondrial dysfunction

Company teams up with BosleyMD on new ‘densifying’ treatment that aims to

‘Five years ago, nobody was talking about longevity – now the whole world is’

Harish Consul on why investing in longevity is a necessity for those